---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-051559"
form_type: "8-K"
ticker: "BRKR"
cik: "0001109354"
company_name: "BRUKER CORP"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:53:45.603881+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion

## Summary
- Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.
- ELITech FY2023 revenue ~€150M with >80% consumables; systems include InGenius and BeGenius MDx platforms.
- Remainder 2024 expected ELITech revenue ~$100M within Bruker, non-GAAP EBIT margins >20%.
- Non-GAAP EPS accretion of $0.08-$0.10 for FY 2024 after acquisition financing costs.
- ELITech to become Bruker Molecular Diagnostics within Microbiology & Infection Diagnostics division.

## SEC filing metadata
- accession: 0000950170-24-051559
- form_type: 8-K
- ticker: BRKR
- cik: 0001109354
- company_name: BRUKER CORP
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/0000950170-24-051559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1109354/000095017024051559/brkr-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-051559
- JSON: https://secwatch.observer/filing/0000950170-24-051559.json
- Plain text: https://secwatch.observer/filing/0000950170-24-051559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.